Loading…
Loading…
Announcements from Anixa Biosciences, published the moment they cross the wire. Get them by email.
2022
Mar 30, 2022
12:45 PM EDT
The initiation of a Phase 1 trial evaluating its novel chimeric antigen receptor T-cell (CAR-T) therapy in ovarian cancer. The CAR-T approach used for Anixa's therapy is known as chimeric endocrine receptor T-cell (CER-T) since the target of the engineered T-cells is an endocrine receptor.
Mar 17, 2022
8:30 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the Company will present at the 2022 Virtual Growth Conference, hosted by M-Vest, a division of Maxim Group LLC, on March 28 th – 30 th from 9:00 am – 5:00 pm…
Jan 25, 2022
8:30 AM EST
The Japanese Patent Office has issued a Decision to Grant of a patent to Cleveland Clinic titled, "Ovarian Cancer Vaccines." The technology was invented by Drs. Vincent K. Tuohy , Suparna Mazumder and Justin M. Johnson at Cleveland Clinic. Anixa is the worldwide licensee for the vaccine technology.
Jan 24, 2022
8:30 AM EST
The company and its partner, MolGenie GmbH, have synthesized a compound that appears to be considerably more potent than nirmatrelvir at inhibiting M pro , the main protease of the SARS-CoV-2 virus. Nirmatrelvir is the main component of Pfizer's PAXLOVID ™ , which was recently authorized to treat COVID-19.
2021
Dec 16, 2021
8:30 AM EST
The Company is participating in the LifeSci Partners 11 th Annual Corporate Access Event, which will be held virtually from January 5-7 , 2022, and the H.C. Wainwright BioConnect Conference, which will be held January 10-13, 2022 .
Dec 07, 2021
8:30 AM EST
The results of a genomic variant analysis done with its partner, MolGenie, GmbH, on potential compounds to treat COVID-19. The data indicate that the compounds in development should be effective against the Omicron variant of SARS-CoV-2, in addition to the previously identified Delta variant of the virus.
Oct 26, 2021
8:35 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ) ("Anixa") a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that, in conjunction with its partner, Cleveland Clinic, it has commenced dosing of patients for a novel study of its vaccine that is being investigated…
Oct 06, 2021
8:30 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the China National Intellectual Property Administration (CNIPA) has issued a Notification of Grant of Patent Right on Anixa's novel Chimeric Antigen…
Oct 01, 2021
8:30 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S.
Sep 14, 2021
8:31 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the inventor of its ovarian cancer CAR-T technology, Dr.
Sep 08, 2021
8:30 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar , Anixa's Chief Executive Officer, will present at the virtual H.C.
Sep 07, 2021
8:30 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today the appointment of Pamela D. Garzone , Ph.D., as Chief Development Officer. Dr.
Aug 30, 2021
8:30 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S.
Aug 25, 2021
8:30 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that a genomic variant analysis indicates that its potential compounds may be even more effective against the Delta variant than the original wild type SARS-CoV-2.
Aug 23, 2021
8:30 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Director, Dr. Arnold Baskies has been appointed to the World Health Organization's (WHO) Global Breast Cancer Initiative.
Aug 18, 2021
8:30 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Patent and Trademark Office has issued the first U.S. patent for its novel ovarian cancer vaccine technology.
May 26, 2021
8:30 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that its ovarian cancer vaccine technology is part of an award from the National Cancer Institute (NCI).
May 20, 2021
8:30 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S.
Apr 19, 2021
8:30 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S.
Apr 05, 2021
8:30 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that based on Proof of Concept (POC) animal study results, it will progress to the next stage of development of its potential anti-viral therapy for Covid-19.
